Teva Pins Long-Term Hopes In MS On Return Of Laquinimod
This article was originally published in Scrip
After missing out on the initial wave of oral multiple sclerosis drugs, Teva Pharmaceutical Industries Ltd. still has its eye on the oral immunomodulator laquinimod as a future pillar for the firm in multiple sclerosis. Teva is hoping for a launch in 2018 after a third and final Phase III trial reads out in 2017.
You may also be interested in...
Access to branded drugs has remained steady, but there has been less management across brands by commercial payers, according to an analysis of the I&I market access environment by Bernstein.
Biopharmaceuticals President Ruud Dobber talked to Scrip about the launches of Lokelma and roxadustat in kidney disease, building with a high bar in cardiovascular disease and expanding in cell and gene therapy.
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.